Anti-Cancer Drug Linked to Tumor Shrinkage in Patients with Advanced Differentiated Thyroid Cancer

Thursday, October 27, 2011 - 16:30 in Health & Medicine

Researchers tested the effectiveness of lenvatinib in patients with advanced, progressive differentiated thyroid cancer (DTC) that does not respond to conventional radioiodine therapy. Data demonstrated a partial response in 45%-50% of the 58 patients enrolled in the study.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net